Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway - PubMed
4 hours ago
- #colorectal-cancer
- #PI3K-Akt-mTOR-pathway
- #ursodeoxycholic-acid
- Ursodeoxycholic acid (UDCA) shows potential therapeutic effects against colorectal cancer (CRC) due to its anti-inflammatory and immunomodulatory properties.
- The study used network pharmacology, molecular docking, and in vivo validation in an AOM/DSS-induced mouse model to explore UDCA's molecular targets and effects on the gut microenvironment.
- UDCA significantly reduced colitis-associated tumorigenesis and tumor burden by inhibiting the PI3K/Akt/mTOR signaling pathway.
- Molecular docking identified EGFR as a key upstream target of UDCA, suppressing the oncogenic PI3K/Akt/mTOR axis.
- UDCA improved the tumor microenvironment by reducing pro-inflammatory cytokines, regulating metabolic gene expression (CYP19A1, HMGCR), and promoting gut microbiota homeostasis.
- The findings suggest UDCA's anti-tumor effects are mediated through EGFR inhibition and partial restoration of the intestinal immune-metabolic microenvironment.